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Objectives: Longitudinal assessment of a Parkinson’s disease (PD) cohort, to investigate the evolution or
REM sleep behavior symptoms (RBD) over time and to test the relation between RBD at onset and motor
dysfunction progression.
Methods: An early stage PD cohort (n ¼ 61) was assessed at two time points, separated by a two years
interval. Diagnostic criteria for RBD were: violent behavior during sleep and body movements or
vocalization indicative of dream enacting and at least six afﬁrmative answers in the REM sleep behavior
disorder screening questionnaire. Motor function assessment was performed with the Uniﬁed Parkin-
son’s Disease Scale part II and III (total and partial scores for tremor, bradykinesia, rigidity, gait/postural
instability and dysarthria).
Results: 25 Patients had RBD at baseline, vs. 35 at follow-up. Three RBD changed to non-RBD at follow-
up, while 10 non-RBD patients developed RBD at follow-up (annual incidence of 12.5%). RBD and non-
RBD patients did not differ signiﬁcantly at baseline or follow-up. The presence of RBD at baseline was
signiﬁcantly related to an increase in UPDRS total and bradykinesia scores over time.
Discussion: RBD symptoms can vary over time and have a tendency to increase during the early stages of
disease. The presence of RBD symptoms could be a risk factor for motor function deterioration and
particularly for bradykinesia worsening.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.spital de Egas Moniz (CHLO),
: þ351 213622459.
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REM-sleep behavior disorder (RBD) is a REM sleep parasomnia
characterized by violent behavior during sleep, related to loss of
Fig. 1. Evolution of RBD symptoms between t0 and t1. Legend: values represent
number of patients.
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can occur in isolation, but is most frequent in patients with neuro-
degenerative disorders, particularly those associated with Lewy
body deposition, like Multiple System Atrophy, Lewy-body de-
mentia and Parkinson’s disease (PD) [2]. In a previous study, we
have presented results from a cross-sectional analysis of a cohort of
early stage PD patients, in which worse non-tremor motor symp-
toms were found to be associated with past or present RBD symp-
toms [3]. Several other cross-sectional studies have suggested that
RBD could be associated with speciﬁc PD phenotypes, comprising a
predominance of postural instability and gait difﬁculties [4e7].
However, there is a need for longitudinal studies, in which the sig-
niﬁcance of RBD as a risk factor can be determinedmore accurately.
We conducted a longitudinal assessment of the previously
mentioned cohort, in order to assess the evolution of RBD over time
and to evaluate the predictive value of RBD for motor dysfunction
progression in PD.
2. Methods
Seventy-ﬁve early stage PD patients, diagnosed according to validated criteria
[8], were consecutively recruited fromHospital Egas Moniz Neurology Department’s
outpatient clinic. All patients had clinically satisfactory response to dopaminergic
treatment, and none presented with cerebellar dysfunction, signs of autonomic
dysfunction, or other signs suggestive of multiple system atrophy or other atypical
parkinsonism. Early stage PD was deﬁned, at baseline, as disease duration (time in
years from appearance of ﬁrst motor symptoms to ﬁrst assessment) up to 5 years
and Hoehn and Yahr (HY) [9] stage from 1 to 2.5, included.
Patients were assessed twice, with a two year interval (t0 and t1), with the same
instruments and by the same observer.
2.1. Motor assessment
Patients were assessed with the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) part II and III [10], after receiving their usual medication and while on on
state. Separated scores were derived for tremor, rigidity, bradykinesia, speech and
gait/postural stability symptoms, from items 20 and 21, 22, 23 to 27, 18, and 29 to 30,
respectively. Patients were split into three motor groups, according to the classiﬁ-
cation system proposed by Jankovic and co-workers [11]: i. tremor predominant; ii.
intermediate; iii. postural instability and gait difﬁculty (PIGD) predominant. Recent
studies have shown that motor phenotype variation over time occurs usually in the
tremor-PIGD direction and that this progression is predictive of worse prognosis
[12]. For statistical purposes, motor status progressionwas deﬁned as a change from
the tremor dominant form to the intermediate or PIGD phenotype, versus mainte-
nance of tremor subtype or a change from intermediate of PIGD subtype to tremor
(patients who had PIGD subtype at baseline and maintained that status were
excluded from this analysis). Dopaminergic treatment was calculated as L-Dopa
equivalent doses (DED) [13].
2.2. RBD assessment
Clinical interview with the patients and bed partners was used to conﬁrm the
presence of minimal clinical criteria for RBD, according to the International Classi-
ﬁcation of Sleep Disorders (ICSD): violent behavior during sleep and body move-
ments or vocalization indicative of dream enacting [14]. Assisted by their bed
partners, the patients also answered the REM sleep behavior disorder screening
questionnaire (RBDSQ), a recently proposed screening tool, which proved to have
great sensitivity and reasonable speciﬁcity for RBD diagnosis as conﬁrmed by pol-
ysomnography [15]. RBDSQ contains 13 questions, covering several aspects of RBD
symptom spectrum. In the original study a score of at least ﬁve positive answers was
proposed as the cut-off value for possible RBD. However, we chose to use 6 as the
cut-off score, as proposed by amore recent investigation, that validated this scale for
use in PD population [16]. Patients who fulﬁlled the ICSDminimal criteria and scored
above cut-off on the RBDSQ were classiﬁed as possible RBD cases (RBDp). Patients
which did not fulﬁll both criteria were classiﬁed has non-RBDp patients.
2.3. Statistical analysis
The annual incidence of RBDp was calculated as the number of new RBDp cases
divided by the time elapsed (in years), divided by the total number of patients
without RBDp at t1. We used the McNemar test to compare the proportion of RBDp
and non-RBDp between baseline and follow-up. Two way independent sample t
tests or ManneWhitney tests (depending on the distribution of the variables) where
used to compare continuous variables at baseline and follow-up, between RBDp and
non-RBDp patients. Repeated measures ANOVA was used to test the relationbetween the presence of RBDp at baseline (between-patients factor) and the vari-
ation of motor scores over time (within-patients variables).
Ethics: Patients and controls signed informed consent forms. The ethics com-
mittee of the institution approved the investigation protocol. The investigation was
performed according to the Declaration of Helsinki.
3. Results
Of the 75 patients assessed at t0, 61 patients were reassessed at
t1. Two patients died, from causes unrelated to PD; 1 refused
reassessment; diagnosis changed in 4, who at follow-up were
found not to have PD; 7 patients could not be found at t2. Patients
who could not be assessed at t1, showed a tendency for older age
(75.4  4.55 vs. 71.9  7.53, p ¼ 0.099), and older age of onset
(72.7  4.75 vs. 69.1  7.76, p ¼ 0.098). There were no signiﬁcant
differences in demographic or motor variables between these pa-
tients and those that were available for reassessment. RBDp prev-
alence was not signiﬁcantly different: 4 (29%) vs. 28 (46%),
p ¼ 0.370.
The number of RBD cases increased from t0 to t1, although the
difference did not reach signiﬁcance (28e35, p ¼ 0.950). Annual
incidence of RBD was 12.5%. Variation from non-RBD to RBD was
more frequent than in the opposite direction, but most patients
maintained the baseline diagnosis (Fig. 1).
Forty-seven patients were on dopaminergic treatment at t0
(mean DED 390  355.8), 18 exclusively on L-Dopa (mean DED
267.2  287.9), 7 exclusively on dopamine agonists (mean DED
170  164.4) and 22 on both (mean DED 674.1  370.7). Four pa-
tients were additionally under treatment with MAO inhibitors (2
with selegiline, two with rasagiline), as a co-adjuvant treatment to
L-Dopa. At t1, 59 patients were on dopaminergic treatment, 21
exclusively on L-Dopa (mean DED 498.4  213.9), 8 exclusively on
dopamine agonists (mean DED 185.0  118.9) and 30 on both
(mean DED 751  370.8). To investigate the relation between
dopaminergic doses increase (calculated as DED at t1 e DED at t0)
and RBD diagnosis change from t0 to t1, we compared total, L-Dopa,
and dopamine agonist doses increase between patients that
changed from to RBDp to non-RBDp, maintained non-RBDp diag-
nosis, maintained RBDp diagnosis or changed from non-RBDp to
RBDp (ANOVA followed by Bonferroni post-hoc analysis). We found
no signiﬁcant differences. Ten patients were on SSRI at t0 (7 had
RBD symptoms) and 1 RBD patient was on clonazepam. There were
no patients on rivastigmine. At t1, 15 patients were on SSRI (11 with
RBD), 5 were on rivastigmine (3with RBD) and 3 on clonazepam (all
RBD patients). There was no signiﬁcant relation between the use of
these medications and the presence of RBD at t0 or t1. Two patients
Table 1
Motor evolution according to RBDp status at onset.
RBDp Non-RBDp F p
t0 t1 t0 t1
HY stage 1.9  0.6 2.4  0.6 1.8  0.6 2.1  0.7 2.660 0.108
UPDRS 20.9  11.2 25.1  11.3 16.7  10.8 19.3  11.3 4.554 0.037*
Tremor 4.0  3.6 2.9  3.8 4.1  3.8 4.0  3.9 0.588 0.446
Rigidity 3.1  3.4 2.8  1.9 1.6  2.6 2.3  2.1 3.568 0.064
Bradykinesia 8.9  6.7 12.0  5.9 6.2  5.6 7.3  6.5 7.752 0.007**
Dysarthria 0.8  0.8 1.0  1.0 0.5  0.7 0.9  0. 9 1.083 0.302
Gait/Posture 1.5  1.2 2.0  1.4 1.3  1.2 1.85  1.2 0.513 0.477
DED 395.3  385.8 537.7  253.7 442.5  446.0 579.9  355.6 0.294 0.590
Values are mean  SD. F and p values represent results of repeated measures ANOVA, used to test the relation between RBD status at t0 and score variation from t0 to t1
*p < 0.05; **p < 0.01.
HY e Hoehn and Yahr stage; UPDRS e Uniﬁed Parkinson Disease Rating Scale total score; DED e L-dopa equivalent doses.
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who were not on SSRI at t0, had started this medication at t1.
Change in SSRI was not signiﬁcantly related with change in RBD
diagnosis (Chi-square tests).
Fifteen patients presented with PIGD phenotype at t0, and
maintained that status at t1, being excluded from motor status
progression analysis. Of the other 46 patients, 16 showed motor
status progression. Nine of these patients had RBDp at t0, a non
signiﬁcant relation (p ¼ 0.352).
RBDp and non-RBDp groups did not differ signiﬁcantly
regarding motor scores, either at t0 or t1. The presence of RBDp at
onset was signiﬁcantly related to increase in UPDRS total scores and
very signiﬁcantly related to increase of bradykinesia scores
(Table 1). Paired samples t test revealed a signiﬁcant (p ¼ 0.032)
increase in bradykinesia in patients who presented RBDp at t0, and
a non signiﬁcant increase in the non-RBD group (p ¼ 0.336).
4. Discussion
We found a high prevalence of RBDp in our early stage PD
cohort. Although most patients retained their baseline RBD diag-
nosis at follow-up, there was a net increase in RBDp cases over
time, with an annual incidence of 12.5%. Lavault and coworkers [17]
found a decrease in RBD cases over a two year follow up and a lower
annual incidence (9%), although they started with a higher preva-
lence of RBD at baseline. In Gjerstad’s et al. study [18], which had a
longer follow-up (8 years, three visits), there was a much larger
ﬂuctuation in RBD symptoms, with only 3 out of 89 patients
maintaining an RBD diagnosis at all three assessments and total
RBD percentages varying from 14.7% at ﬁrst assessment, to 27.3% on
the second visit and 14.6% at the last appointment. Divergences
regarding previous studies could be caused by differences in PD
populations, as ours was a selected, early stage cohort. A shorter
follow-up time and different case ascertainment method (Gjer-
stad’s study was population based) may also have contributed to
these differences. Also, each of the three studies based RBD diag-
nosis in a different questionnaire, which could have resulted in
different diagnosis rates. All in all, results from our study and those
of Lavault and Gjerstad’s, suggest that RBD symptoms suffer ﬂuc-
tuations over time, which are probably less expressive in the early
stages of disease, according to our results. This should be taken into
account when interpreting RBD prevalence results obtained in
questionnaire based, cross-sectional analysis.
Our results suggest that RBD could be associatedwithworsening
of PD motor symptoms, and particularly of bradykinesia. We found
only one longitudinal study that has assessed the relation between
RBD and progression of motor symptoms [17], which did not ﬁnd
signiﬁcant associations. This study used a different categorization of
motor function: symptoms were aggregated in dopamine and non-dopamine responsive symptoms, and bradykinesia was not studied
separately. Several cross-sectional studies have suggested that RBD
could be associated with worse motor symptoms. Sixel-Döring and
collaborators [6] found that RBD was related to higher HY motor
stage and falls. In Lee and collaborators study [4], RBD patients had a
lower proportion of their UPDRS scores accounted for by tremor,
compared to thosewithoutRBD.Kumru [7] also foundanassociation
between RBD and non-tremor symptoms, as well as Postuma and
collaborators [5]. Our own cross-sectional study, showed a higher
prevalence of PIGD phenotype in patients with present or past RBD
symptoms [3]. These ﬁndings suggest a relation between RBD and
axial, gait and equilibrium related symptoms. This remains amatter
of debate, however, as recent studieswere unable toﬁndworse gait/
postural dysfunction in PD-RBD patients compared to PD patients
without RBD [19]. Our data argues against an association between
RBD and PIGD phenotype. To our knowledge, our study is the ﬁrst to
ﬁnd a longitudinal relation between RBD and bradykinesia. This
difference is relevant at a pathophysiological level, as bradykinesia
shows a strong relation with substantia nigra degeneration and
dopaminergic deﬁcits [20]. There are studies that point to a relation
between the presence of RBD and a decrease in dopaminergic
function on the striatum in functional imaging [21] (although other
studies have in turn contradicted these results [22]). Our results
could suggest that RBD is associated with a faster progression of
neuronal loss in substantia nigra.
The present investigation has some limitations. Like in most of
the longitudinal studies performed so far, and many of the cross-
sectional studies, RBD diagnosis was based on clinical criteria and
a questionnaire, instead of polysomnography. This method does not
take in account asymptomatic cases (i.e. REM sleep without atonia
cases). On the other hand, the lower speciﬁcity of the RBDSQ could
have resulted in an overestimation of RBDp cases. We should also
point that the test-retest reliability of RBDSQwas not investigated in
the PD validation study. RBD assessment at t0 could have increased
bed-partners awareness for mild symptoms, as previously reported
byPostumaet al. [23], resulting in an increase of RBDcases at follow-
up. As advantages, we should refer the longitudinal nature of the
study, in a ﬁeld which is lacking this kind of methodology, and the
different categorization of motor function, which has allowed us to
ﬁnd a speciﬁc relation between RBD and bradykinesia.
In conclusion, our results suggest that RBD symptoms can vary
over time, and that the presence of RBD could be a risk factor for
motor function deterioration and particularly for bradykinesia
worsening.
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